These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 18044812)

  • 1. Structure-based design of a bicyclic peptide antagonist of the vascular endothelial growth factor receptors.
    Goncalves V; Gautier B; Garbay C; Vidal M; Inguimbert N
    J Pept Sci; 2008 Jun; 14(6):767-72. PubMed ID: 18044812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational design, structure, and biological evaluation of cyclic peptides mimicking the vascular endothelial growth factor.
    Goncalves V; Gautier B; Coric P; Bouaziz S; Lenoir C; Garbay C; Vidal M; Inguimbert N
    J Med Chem; 2007 Oct; 50(21):5135-46. PubMed ID: 17900101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disulfide and amide-bridged cyclic peptide analogues of the VEGF₈₁₋₉₁ fragment: synthesis, conformational analysis and biological evaluation.
    García-Aranda MI; Mirassou Y; Gautier B; Martín-Martínez M; Inguimbert N; Vidal M; García-López MT; Jiménez MA; González-Muñiz R; Pérez de Vega MJ
    Bioorg Med Chem; 2011 Dec; 19(24):7526-33. PubMed ID: 22078412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating the differential activation of vascular endothelial growth factor (VEGF) receptors.
    Horta BA; Sodero AC; de Alencastro RB
    J Mol Graph Model; 2009 Oct; 28(3):287-96. PubMed ID: 19734078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for the interaction of a vascular endothelial growth factor mimic peptide motif and its corresponding receptors.
    Giordano RJ; Anobom CD; Cardó-Vila M; Kalil J; Valente AP; Pasqualini R; Almeida FC; Arap W
    Chem Biol; 2005 Oct; 12(10):1075-83. PubMed ID: 16242650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors.
    Peifer C; Selig R; Kinkel K; Ott D; Totzke F; Schächtele C; Heidenreich R; Röcken M; Schollmeyer D; Laufer S
    J Med Chem; 2008 Jul; 51(13):3814-24. PubMed ID: 18529047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and pharmacological evaluation of cyclic mimetics of the insulin-like peptide 3 (INSL3) B-chain.
    Shabanpoor F; Bathgate RA; Hossain MA; Giannakis E; Wade JD; Hughes RA
    J Pept Sci; 2007 Feb; 13(2):113-20. PubMed ID: 17120268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of vascular endothelial growth factor cotranslational translocation by the cyclopeptolide CAM741.
    Harant H; Wolff B; Schreiner EP; Oberhauser B; Hofer L; Lettner N; Maier S; de Vries JE; Lindley IJ
    Mol Pharmacol; 2007 Jun; 71(6):1657-65. PubMed ID: 17369307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative VEGF receptor tyrosine kinase modeling for the development of highly specific inhibitors of tumor angiogenesis.
    Schmidt U; Ahmed J; Michalsky E; Hoepfner M; Preissner R
    Genome Inform; 2008; 20():243-51. PubMed ID: 19425138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BI-32169, a bicyclic 19-peptide with strong glucagon receptor antagonist activity from Streptomyces sp.
    Potterat O; Wagner K; Gemmecker G; Mack J; Puder C; Vettermann R; Streicher R
    J Nat Prod; 2004 Sep; 67(9):1528-31. PubMed ID: 15387654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor activates the Tie family of receptor tyrosine kinases.
    Singh H; Milner CS; Aguilar Hernandez MM; Patel N; Brindle NP
    Cell Signal; 2009 Aug; 21(8):1346-50. PubMed ID: 19376222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
    Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia.
    Sela S; Itin A; Natanson-Yaron S; Greenfield C; Goldman-Wohl D; Yagel S; Keshet E
    Circ Res; 2008 Jun; 102(12):1566-74. PubMed ID: 18515749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular Endothelial Growth Factor Peptide Ligands Explored by Competition Assay and Isothermal Titration Calorimetry.
    Reille-Seroussi M; Gaucher JF; Desole C; Gagey-Eilstein N; Brachet F; Broutin I; Vidal M; Broussy S
    Biochemistry; 2015 Aug; 54(33):5147-56. PubMed ID: 26222917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparison of VEGFR-1-binding domain of VEGF-A with modelled VEGF-C sheds light on receptor specificity.
    Kasap M; Sazci A
    J Theor Biol; 2008 Aug; 253(3):446-51. PubMed ID: 18479712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical and structural analysis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist.
    Gautier B; Goncalves V; Diana D; Di Stasi R; Teillet F; Lenoir C; Huguenot F; Garbay C; Fattorusso R; D'Andrea LD; Vidal M; Inguimbert N
    J Med Chem; 2010 Jun; 53(11):4428-40. PubMed ID: 20462213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
    Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.